Guobin Fu

557 total citations
31 papers, 448 citations indexed

About

Guobin Fu is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Guobin Fu has authored 31 papers receiving a total of 448 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 11 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Guobin Fu's work include Cancer Immunotherapy and Biomarkers (8 papers), HER2/EGFR in Cancer Research (4 papers) and Gut microbiota and health (4 papers). Guobin Fu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), HER2/EGFR in Cancer Research (4 papers) and Gut microbiota and health (4 papers). Guobin Fu collaborates with scholars based in China, Singapore and United Kingdom. Guobin Fu's co-authors include Ming Yang, Liqing Zhou, Jinyu Wei, Qipeng Yuan, Juan Shi, Chao Lü, Fang Sun, Xiaojiao Zhang, Changchun Zhou and Jianping Wu and has published in prestigious journals such as Nature, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Guobin Fu

26 papers receiving 446 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Guobin Fu China 10 313 226 91 54 37 31 448
Shouru Zhang China 12 331 1.1× 139 0.6× 131 1.4× 64 1.2× 26 0.7× 18 439
Jialin Feng China 12 310 1.0× 230 1.0× 55 0.6× 42 0.8× 38 1.0× 22 430
Zhenbing Lv China 12 373 1.2× 237 1.0× 66 0.7× 35 0.6× 16 0.4× 20 463
Fang Wu China 14 431 1.4× 178 0.8× 100 1.1× 46 0.9× 31 0.8× 28 528
Lanping Zhou China 15 362 1.2× 166 0.7× 130 1.4× 71 1.3× 61 1.6× 23 523
Kathleen Woods Ignatoski United States 3 225 0.7× 192 0.8× 115 1.3× 85 1.6× 36 1.0× 3 370
Xianjun Zhu China 7 255 0.8× 134 0.6× 85 0.9× 77 1.4× 26 0.7× 13 396

Countries citing papers authored by Guobin Fu

Since Specialization
Citations

This map shows the geographic impact of Guobin Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guobin Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guobin Fu more than expected).

Fields of papers citing papers by Guobin Fu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guobin Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guobin Fu. The network helps show where Guobin Fu may publish in the future.

Co-authorship network of co-authors of Guobin Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Guobin Fu. A scholar is included among the top collaborators of Guobin Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guobin Fu. Guobin Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Jingliang, Weihao Wang, Bin Liu, et al.. (2025). Serum zinc as a biomarker to predict the efficacy of immune checkpoint inhibitors in cancers. PLoS ONE. 20(7). e0326057–e0326057.
2.
Wang, Weihao, et al.. (2025). PLK1 in cancer therapy: a comprehensive review of immunomodulatory mechanisms and therapeutic opportunities. Frontiers in Immunology. 16. 1602752–1602752. 3 indexed citations
3.
Wang, Yahui, et al.. (2025). Polysaccharide from Atractylodes macrocephala Koidz. alleviates pyrotinib-induced diarrhea through regulating cAMP/LKB1/AMPK/CFTR pathway and restoring gut microbiota and metabolites. International Journal of Biological Macromolecules. 308(Pt 3). 142512–142512. 1 indexed citations
4.
Luan, Fang, Jingliang Wang, Lei Liu, et al.. (2024). Serum iron element: A novel biomarker for predicting PD-1 immunotherapy efficacy. International Immunopharmacology. 131. 111823–111823. 5 indexed citations
5.
Zhao, Rui-Lin, Shu Yang, Wei Xu, et al.. (2024). The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis. Cancer Cell International. 24(1). 361–361. 2 indexed citations
6.
Wang, Yahui, et al.. (2024). Immunogenicity and Safety of COVID-19 Vaccines in Patients with Lung Cancer: Results of a Systematic Review and Meta-Analysis. International Archives of Allergy and Immunology. 186(6). 594–605. 1 indexed citations
7.
Pan, Liyin, Junlei Zhang, Wei Xu, et al.. (2024). Mechanism of Atractylenolide Ⅲ alleviating pyrotinib-induced diarrhea by regulating AMPK/CFTR pathway through metabolite of gut microbiota. Journal of Traditional and Complementary Medicine. 15(2). 192–204. 2 indexed citations
8.
Liu, Lei, Junlei Zhang, Wei Xu, et al.. (2023). HER2-positive breast cancer progresses rapidly after pyrotinib resistance: acquired RET gene fusion and TP53 gene mutation are potential reasons. Anti-Cancer Drugs. 34(10). 1196–1201. 3 indexed citations
9.
Liu, Lei, Jing Zhao, Jingliang Wang, et al.. (2023). The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer. Journal of Cancer. 14(6). 952–965. 9 indexed citations
10.
Xu, Wei, et al.. (2023). Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis. Frontiers in Immunology. 14. 1251645–1251645. 3 indexed citations
11.
Xu, Wei, Lei Liu, Junlei Zhang, et al.. (2023). Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation. The Oncologist. 28(6). e416–e424. 3 indexed citations
12.
Liu, Lei, Xiaoying Xu, Hongjing Liu, et al.. (2022). Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics. Anti-Cancer Drugs. 34(6). 747–762. 6 indexed citations
13.
Liu, Lei, Jingliang Wang, Wei Xu, et al.. (2022). Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations. Journal of Cancer Research and Clinical Oncology. 149(5). 2029–2039. 4 indexed citations
14.
Han, Dali, Guobin Fu, Chengxin Liu, et al.. (2019). <p>Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study</p>. OncoTargets and Therapy. Volume 12. 1681–1689. 6 indexed citations
15.
Fu, Guobin, Jing Wu, Lishan Zhang, et al.. (2016). 4-cholesten-3-one suppresses lung adenocarcinoma metastasis by regulating translocation of HMGB1, HIF1α and Caveolin-1. Cell Death and Disease. 7(9). e2372–e2372. 31 indexed citations
16.
Pan, Wenting, Liqing Zhou, Minghua Ge, et al.. (2016). Whole exome sequencing identifies lncRNAGAS8-AS1andLPAR4as novel papillary thyroid carcinoma driver alternations. Human Molecular Genetics. 25(9). 1875–1884. 71 indexed citations
17.
Zhang, Xiaojiao, Liqing Zhou, Guobin Fu, et al.. (2014). The identification of an ESCC susceptibility SNP rs920778 that regulates the expression of lncRNAHOTAIRvia a novel intronic enhancer. Carcinogenesis. 35(9). 2062–2067. 147 indexed citations
18.
Wang, Tingliang, Guobin Fu, Xiaojing Pan, et al.. (2013). Structure of a bacterial energy-coupling factor transporter. Nature. 497(7448). 272–276. 58 indexed citations
19.
Zheng, Hongwei, Guobin Fu, Jingsong Yuan, et al.. (2012). Suppression of non-small cell lung cancer proliferation and tumorigenicity by DENND2D. Lung Cancer. 79(2). 104–110. 17 indexed citations
20.
Yuan, Jingsong, Jinfang Ma, Hongwei Zheng, et al.. (2008). Overexpression of OLC1, Cigarette Smoke, and Human Lung Tumorigenesis. JNCI Journal of the National Cancer Institute. 100(22). 1592–1605. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shouru Zhang Breakdown of academic impact, for papers by Jialin Feng Breakdown of academic impact, for papers by Zhenbing Lv Breakdown of academic impact, for papers by Fang Wu Breakdown of academic impact, for papers by Lanping Zhou Breakdown of academic impact, for papers by Kathleen Woods Ignatoski Breakdown of academic impact, for papers by Xianjun Zhu
Rankless by CCL
2026